Bioversys Ag

Eth Zurich

Marc Gitzinger

Glenn E Dale

Sergio Lociuro

Christian Kemmer

Marilyne Bourotte

Stefano Biondi

Peter Schneider

Nicolas Willand

Vincent Trebosc

Martin Fussenegger

Marcel Tigges

Daniel Gygax

Wilfried Weber

Ronald Schoenmakers

Michael Brand

Rainer Riedl

Peter Spies

Michel Pieren

Assaf Levi

Mark Sephton

Birgit Schellhorn

Patrik Zueger

Julian Schill

Mathieu Maingot

Olivier Defert

Kevin Antraygues

Bruna Gioia

The invention provides formulations containing highly concentrated solutions of rifabutin and methods of making such formulations. The invention also provides methods of using such formulations to treat a bacterial infection in a subject.

Rifabutin treatment methods, uses, and compositions

The invention provides antibiotic combination therapies for treating aninfection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Antibiotic combination therapies

The invention provides systems and methods for increased clinical efficacy of rifabutin against. The invention takes advantage of the discovery of a ferric-coprogen (FhuE) receptor that is responsible for the uptake of rifabutin intocells. Methods preferably include obtaining a sample from a patient suspected of having an infection; performing a test on the sample to identify an infection ofin the patient; and providing a formulation of rifabutin for treating the patient that, when administered to the patient, maximizes a resultant AUC and/or C. The method may include administering the formulation of rifabutin to the patient. Preferably the formulation is delivered to the patient, e.g., by intravenous injection and results in a Cis that greater than about 2 mg/L and optionally less than about 50 mg/L.

The invention relates to compounds and pharmaceutical compositions useful in combination with tetracyclines in the treatment of bacterial infections caused by Gram-positive and Gram-negative pathogens, with particular efficacy in tetracycline resistant strains. These compounds specifically bind to TetR and therefore prevent the transcriptional activation of tet resistance genes. The compounds have a potentiating effect on the activity of members of the tetracycline family, in particular of tetracycline, minocycline, doxycycline and tigecycline, in the treatment of tetracycline susceptible, intermediate and tetracycline resistant pathogens.

Composition for treatment of pathogens that are resistant to tetracyclines

The invention relates to a pharmaceutical composition comprising a compound of formula (1) wherein Ris optionally substituted phenyl, optionally substituted pyridyl or optionally substituted indolyl; Ris (CH)wherein n is 0, 1, 2, 3 or 4; Ris (CH)Rwherein m is 0, 1, 2, 3 or 4, and Ris methyl, isopropyl, tert-butyl, OCH, OH, optionally substituted phenoxy, C&#x2261;CH, C&#x2261;N, optionally substituted phenyl, furanyl or thienyl; A is a ring containing Xwith the meaning O, S, NH, N(CH) or CH; and Xis O, S or NH; and a compound of formula (2) wherein Ris optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, &#x2014;NRR; or &#x2014;NH&#x2014;N&#x2550;CH&#x2014;R; and substituents Rto Rhave the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis. 

Composition for treatment of tuberculosis

The invention relates to the use of a skin permeating compound such as phloretin for controlling transgene expression under control of theDOT-T1E-derived bacterial repressor TtgR, to a vector comprising the genetic code for the repressor TtgR fused to a transactivation or a transrepressor domain, to a vector comprising a TtgR-specific operator sequence (O), a promoter and a polynucleotide coding for an endogenous or exogenous protein, and to a mammalian cell transiently or constitutively transfected with the mentioned vectors, and to mammals comprising such cells in nano- or microcontainers.

Controlling transgene expression across the skin

Growing community of inventors

Binningen, Switzerland

Marc Gitzinger